Holen Sie sich die Stockscreener-App
205.79
1.83%
-3.83
Handel nachbörslich:
205.79
Schlusskurs vom Vortag:
$209.62
Offen:
$207.58
24-Stunden-Volumen:
1.14M
Relative Volume:
1.75
Marktkapitalisierung:
$10.63B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$431.79M
KGV:
21.82
EPS:
9.43
Netto-Cashflow:
$486.92M
1W Leistung:
+3.62%
1M Leistung:
+1.62%
6M Leistung:
-23.26%
1J Leistung:
-1.36%
1-Tages-Spanne:
$203.32
$208.03
1-Wochen-Bereich:
$199.31
$213.61
52-Wochen-Spanne:
$161.65
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories International (NYSE:CRL) Given New $190.00 Price Target at Robert W. Baird - MarketBeat
Cell & Gene Therapy Manufacturing Services Market Size, Opportunities, and Growth Strategies 2024-2033 - WhaTech
For the first time in four years, the Charles River experiences a cyanobacteria bloom - Boston 25 News
What is Charles River Laboratories International Inc. (CRL) Stock Return on Shareholders’ Capital? - SETE News
Envestnet Asset Management Inc. Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Envestnet Asset Management Inc. Buys 11,514 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Ori Biotech and Charles River Laboratories Collaborate to - GlobeNewswire
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance
Ori doubles down on Charles River collaboration with promising new data on its automated cell therapy platform - FiercePharma
16,725 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Edgestream Partners L.P. - MarketBeat
Pediatric Clinical Trials Market Future Business - openPR
Robert W. Baird downgrades Charles River Laboratories International Inc. (CRL) stock to a Neutral - Knox Daily
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Dai ichi Life Insurance Company Ltd - MarketBeat
Mizuho highlights cost-saving focus amid challenges for Charles River stock - Investing.com
Charles River teams up with CEBINA for neurodegeneration - Investing.com
Charles River teams up with CEBINA for neurodegeneration By Investing.com - Investing.com Canada
Charles River teams up with CEBINA for neurodegeneration By Investing.com - Investing.com Australia
Mizuho highlights cost-saving focus amid challenges for Charles River stock - Investing.com Australia
Forsta AP Fonden Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Charles River teams up with CEBINA for neurodegeneration - Investing.com India
Charles River teams up with CEBINA for neurodegeneration By Investing.com - Investing.com UK
Mizuho highlights cost-saving focus amid challenges for Charles River stock - Investing.com Canada
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research - StockTitan
Global firm with North Carolina operations to lay off hundreds - Triangle Business Journal
Biopharma Layoff Tracker 2024: Oncternal, Biosense Webster, Charles River Laboratories and More Cut Staff - BioSpace
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Oppenheimer Asset Management Inc. - MarketBeat
Wedbush Securities Inc. Has $271,000 Stock Holdings in CRH plc (NYSE:CRH) - Defense World
Charles River Labs to cut over 600 jobs - The Boston Globe
Charles River Labs to lay off 650 employees - NBC Boston
Charles River Labs to lay off 650 workers in 2024 - The Business Journals
Cell-Based Assays Market Size to Grow at 6.4% CAGR and Surpass USD 40.4 Billion by 2034 Amid Rising Research Applications | According to Transparency Market Research Inc. - GlobeNewswire Inc.
Quest Partners LLC Raises Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching - Simply Wall St
Mawer Investment Management Ltd. Grows Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Van Berkom & Associates Inc. Grows Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
CRL Stock May Benefit From New Neuroscience Research Collaboration - Yahoo Finance
Anchor Capital Advisors LLC Sells 4,599 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Principal Financial Group Inc. - MarketBeat
Charles River Laboratories International (CRL) Fell Due to a More Cautious Funding Environment - MSN
Jensen Investment Management Inc. Trims Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Higher Interest Environment Negatively Impacted Charles River Laboratories (CRL) - Insider Monkey
Higher Interest Environment Negatively Impacted Charles River Laboratories (CRL) - Yahoo Finance
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates - GlobeNewswire
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories’ Directors and Officers - EIN News
$6.1 Bn Vaccine Contract Manufacturing Market by Vaccine Type, Workflow, Application, and Region 2024-2032 - GlobeNewswire Inc.
Global Viral Inactivation Market Size To Worth USD 1915.2 Million By 2033 | CAGR Of 11.35% - GlobeNewswire Inc.
Charles River, Insightec partner on neuroscience drug delivery - Investing.com
Mesirow Institutional Investment Management Inc. Purchases New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience - sharewise
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):